Kognitiv enhancement -- mental præstationsforøgelse gennem farmakologiske interventioner -- er i 2026 et milliarddollarsmarked. Ud over klassikerne (racetamer, koffein, modafinil) rykker tryptaminer ind i fokus for neuroenhancement-forskningen. Hypotesen: Sub-perceptiv 5-HT2A-aktivering fremmer synaptisk plasticitet og øger kognitiv fleksibilitet. Hvor evidensen står, og hvor spekulationen begynder -- det afklarer denne artikel.

Det mest spændende spor fører til neuroplasticiteten. David Olson og kolleger (UC Davis) præciserede i 2018 begrebet "psykoplastogener" -- stoffer, der fremmer synaptisk plasticitet. Deres forskning viste: Psykedeliske tryptaminer øger dendritisk spinogenese, synaptogenese og neuritogenese i kortikale neuroner. Lignende vækstfaktoren BDNF (Brain-Derived Neurotrophic Factor).

Det afgørende punkt: Disse effekter optrådte også ved sub-hallucinogene doser. En undersøgelse fra 2023 viste, at selv doser under adfærdsgrænsen øgede spinogenesen i museneuroner. Hvad det betyder for enhancement? En mikrodosis kunne langvarigt ændre hjernens hardware -- de synaptiske forbindelser -- uden at du akut mærker noget som helst.

Controlled Studies (2023-2026)

A handful of controlled studies have put cognitive performance under psychedelic microdoses to the test:

• Hutten et al. 2023: Low-dose psilocybin improved divergent thinking (Alternative Uses Task) but not convergent thinking (Remote Associates Test). n=60, double-blind, placebo-controlled.
• Yanakieva et al. 2022: Low-dose LSD altered time perception, compressing subjective time estimates – a marker potentially relevant to flow state access.
• Szigeti et al. 2021: Large-scale self-blinding study (n=191) found that perceived microdosing benefits were largely indistinguishable from placebo, suggesting significant expectation effects.

What Remains Unknown

The gaps are large. No study has looked at 4-Pro-MET for cognitive enhancement specifically. Long-term cognitive outcome data for any tryptamine microdosing protocol? Doesn't exist. Whether sub-perceptual doses actually drive measurable neuroplasticity in humans is still unconfirmed. And if cognitive benefits are real, we don't know whether they last once someone stops microdosing.

So where does 4-Pro-MET fit? As a prodrug, it brings practical features to the table: better stability than direct-acting tryptamines, a smoother onset, and a 5-8 hour duration that gives a longer window compared to 4-HO-MET's 4-6 hours. The prodrug mechanism itself may produce a more gradual release of the active compound – useful for any protocol requiring steady effects.

But let's be direct. 4-Pro-MET hasn't been studied in any clinical context. Its cognitive enhancement potential is theory, based on shared receptor mechanisms with better-studied compounds. The compound first hit the research chemical market in August/September 2025. That's too recent for longitudinal data of any kind.